CREALIGHTS (01191) has been included in the Stock Connect program for Hong Kong stocks.
Haiguangxin Zheng (01191) announced that, according to the notices on the adjustment of eligible securities under the Stock Connect scheme issued by the Shanghai Stock Exchange on September 4, 2026, and the Shenzhen Stock Exchange on September 7, 2026, the company has been included in the list of eligible securities under the Stock Connect programs, effective from September 7, 2026. After being included in the list, eligible investors in mainland China will be able to buy and sell shares directly through the Shanghai Stock Exchange and the Shenzhen Stock Exchange.
CREALIGHTS (01191) announced that, according to the notifications issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange on September 4, 2026, and September 7, 2026, respectively, regarding the adjustment of eligible securities for Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect and the adjustment of the list of securities under the Shenzhen-Hong Kong Stock Connect, the company has been included in the list of eligible securities under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, effective September 7, 2026. After being included in the list, qualified investors in mainland China will be able to directly buy and sell shares through the Shanghai Stock Exchange and the Shenzhen Stock Exchange.
The board of directors believes that the inclusion of the shares in the trading mechanism of the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect reflects the market's high recognition of the company's investment value and growth prospects. The company expects that being included in the list of eligible securities will help further expand the company's shareholder base, attract more long-term institutional investors, enhance the liquidity of the shares, lay a solid foundation for the company's long-term development, and thereby increase the company's investment value and reputation in the capital markets.
Related Articles

ONEWO (02602) repurchased 250,000 shares at a cost of approximately HKD 4.7258 million on September 7.

Chongqing Zhifei Biological Products (300122.SZ): The recombinant rotavirus subunit vaccine (Escherichia coli) has obtained approval for clinical trials.

Jiangsu Hengrui Pharmaceuticals (600276.SH) subsidiary SHR-1179 injection has been approved to conduct clinical trials.
ONEWO (02602) repurchased 250,000 shares at a cost of approximately HKD 4.7258 million on September 7.

Chongqing Zhifei Biological Products (300122.SZ): The recombinant rotavirus subunit vaccine (Escherichia coli) has obtained approval for clinical trials.

Jiangsu Hengrui Pharmaceuticals (600276.SH) subsidiary SHR-1179 injection has been approved to conduct clinical trials.

RECOMMEND





